Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Hand bone loss in early rheumatoid arthritis during a methotrexate-based treat-to-target strategy with or without adalimumab-a substudy of the optimized treatment algorithm in early RA (OPERA) trial

Research output: Contribution to journalJournal articleResearchpeer-review

Harvard

Ørnbjerg, LM, Østergaard, M, Jensen, T, Hørslev-Petersen, K, Stengaard-Pedersen, K, Junker, P, Ellingsen, T, Ahlquist, P, Lindegaard, H, Linauskas, A, Schlemmer, A, Dam, MY, Hansen, I, Lottenburger, T, Ammitzbøll, CG, Jørgensen, A, Krintel, SB, Raun, J, Hetland, ML, Slot, O, Nielsen, LK, Skjødt, H, Majgaard, O, Lorenzen, T, Horn, HC, Kowalski, M, Johansen, IL, Pedersen, PM, Manilo, N & Bliddal, H 2017, 'Hand bone loss in early rheumatoid arthritis during a methotrexate-based treat-to-target strategy with or without adalimumab-a substudy of the optimized treatment algorithm in early RA (OPERA) trial' Clinical Rheumatology, vol. 36, no. 4, pp. 781-789. https://doi.org/10.1007/s10067-016-3489-1

APA

CBE

Ørnbjerg LM, Østergaard M, Jensen T, Hørslev-Petersen K, Stengaard-Pedersen K, Junker P, Ellingsen T, Ahlquist P, Lindegaard H, Linauskas A, Schlemmer A, Dam MY, Hansen I, Lottenburger T, Ammitzbøll CG, Jørgensen A, Krintel SB, Raun J, Hetland ML, Slot O, Nielsen LK, Skjødt H, Majgaard O, Lorenzen T, Horn HC, Kowalski M, Johansen IL, Pedersen PM, Manilo N, Bliddal H. 2017. Hand bone loss in early rheumatoid arthritis during a methotrexate-based treat-to-target strategy with or without adalimumab-a substudy of the optimized treatment algorithm in early RA (OPERA) trial. Clinical Rheumatology. 36(4):781-789. https://doi.org/10.1007/s10067-016-3489-1

MLA

Vancouver

Author

Ørnbjerg, L M ; Østergaard, M ; Jensen, T ; Hørslev-Petersen, K ; Stengaard-Pedersen, K ; Junker, P ; Ellingsen, T ; Ahlquist, P ; Lindegaard, H ; Linauskas, A ; Schlemmer, A ; Dam, M Y ; Hansen, I ; Lottenburger, T ; Ammitzbøll, C G ; Jørgensen, A ; Krintel, S B ; Raun, J ; Hetland, M L ; Slot, Ole ; Nielsen, Lars Kjær ; Skjødt, Henrik ; Majgaard, Ole ; Lorenzen, Tove ; Horn, Hans Christian ; Kowalski, Marcin ; Johansen, Inger Lauge ; Pedersen, Peter Mosborg ; Manilo, Natalia ; Bliddal, Henning. / Hand bone loss in early rheumatoid arthritis during a methotrexate-based treat-to-target strategy with or without adalimumab-a substudy of the optimized treatment algorithm in early RA (OPERA) trial. In: Clinical Rheumatology. 2017 ; Vol. 36, No. 4. pp. 781-789.

Bibtex

@article{e4810447eaa7454d8a5b75036af2911e,
title = "Hand bone loss in early rheumatoid arthritis during a methotrexate-based treat-to-target strategy with or without adalimumab-a substudy of the optimized treatment algorithm in early RA (OPERA) trial",
abstract = "This study aims to investigate 1-year hand bone loss (HBL1-year) in early rheumatoid arthritis (RA) patients treated with a methotrexate (MTX) and intra-articular triamcinolone treat-to-target strategy +/- adalimumab and to determine if HBL6months is associated with radiographic progression after 2 years. In a clinical trial (OPERA) of 180 treatment-naive early RA patients, bone mineral density (BMD) was estimated from hand radiographs with digital X-ray radiogrammetry (DXR) at baseline, after 6 (n = 90) and 12 months (n = 70) of follow-up. Baseline and 2-year radiographs were scored according to the Sharp/van der Heijde method. Baseline characteristics and HBL6months (0-6 months changes in DXR-BMD) were investigated as predictors of structural damage by univariate linear (∆ total Sharp/van der Heijde score (TSS) as dependent variable) and logistic (+/-radiographic progression (∆TSS >0) as dependent variable) regression analyses. Variables with p < 0.10 were included in multivariable models. In 70 patients with available HBL1-year data, HBL1-year was median (interquartile range (IQR)) -1.9 (-3.3; -0.26 mg/cm(2)) in the MTX + placebo group and -1.8 (-3.6; 0.06) mg/cm(2) in the MTX + adalimumab group, p = 0.98, Wilcoxon signed-rank. Increased HBL (compared to general population reference values) was found in 26/37 and 23/33 patients in the MTX + placebo and MTX + adalimumab groups, chi-squared = 0.99. In 90 patients with HBL6months data and 2-year radiographic data, HBL6months was independently associated with ∆TSS after 2 years (β = -0.086 (95{\%} confidence interval = -0.15; -0.025) TSS unit/mg/cm(2) increase, p = 0.006) but not with presence of radiographic progression (∆TSS >0) (OR 0.96 (0.92-1.0), p = 0.10). In early RA patients treated with a methotrexate-based treat-to-target strategy, the majority of patients had increased HBL1-year, irrespective of adalimumab; HBL6months was independently associated with ∆TSS after 2 years.",
keywords = "Journal Article",
author = "{\O}rnbjerg, {L M} and M {\O}stergaard and T Jensen and K H{\o}rslev-Petersen and K Stengaard-Pedersen and P Junker and T Ellingsen and P Ahlquist and H Lindegaard and A Linauskas and A Schlemmer and Dam, {M Y} and I Hansen and T Lottenburger and Ammitzb{\o}ll, {C G} and A J{\o}rgensen and Krintel, {S B} and J Raun and Hetland, {M L} and Ole Slot and Nielsen, {Lars Kj{\ae}r} and Henrik Skj{\o}dt and Ole Majgaard and Tove Lorenzen and Horn, {Hans Christian} and Marcin Kowalski and Johansen, {Inger Lauge} and Pedersen, {Peter Mosborg} and Natalia Manilo and Henning Bliddal",
note = "COPECARE",
year = "2017",
month = "4",
day = "1",
doi = "10.1007/s10067-016-3489-1",
language = "English",
volume = "36",
pages = "781--789",
journal = "Clinical Rheumatology",
issn = "0770-3198",
publisher = "Springer U K",
number = "4",

}

RIS

TY - JOUR

T1 - Hand bone loss in early rheumatoid arthritis during a methotrexate-based treat-to-target strategy with or without adalimumab-a substudy of the optimized treatment algorithm in early RA (OPERA) trial

AU - Ørnbjerg, L M

AU - Østergaard, M

AU - Jensen, T

AU - Hørslev-Petersen, K

AU - Stengaard-Pedersen, K

AU - Junker, P

AU - Ellingsen, T

AU - Ahlquist, P

AU - Lindegaard, H

AU - Linauskas, A

AU - Schlemmer, A

AU - Dam, M Y

AU - Hansen, I

AU - Lottenburger, T

AU - Ammitzbøll, C G

AU - Jørgensen, A

AU - Krintel, S B

AU - Raun, J

AU - Hetland, M L

AU - Slot, Ole

AU - Nielsen, Lars Kjær

AU - Skjødt, Henrik

AU - Majgaard, Ole

AU - Lorenzen, Tove

AU - Horn, Hans Christian

AU - Kowalski, Marcin

AU - Johansen, Inger Lauge

AU - Pedersen, Peter Mosborg

AU - Manilo, Natalia

AU - Bliddal, Henning

N1 - COPECARE

PY - 2017/4/1

Y1 - 2017/4/1

N2 - This study aims to investigate 1-year hand bone loss (HBL1-year) in early rheumatoid arthritis (RA) patients treated with a methotrexate (MTX) and intra-articular triamcinolone treat-to-target strategy +/- adalimumab and to determine if HBL6months is associated with radiographic progression after 2 years. In a clinical trial (OPERA) of 180 treatment-naive early RA patients, bone mineral density (BMD) was estimated from hand radiographs with digital X-ray radiogrammetry (DXR) at baseline, after 6 (n = 90) and 12 months (n = 70) of follow-up. Baseline and 2-year radiographs were scored according to the Sharp/van der Heijde method. Baseline characteristics and HBL6months (0-6 months changes in DXR-BMD) were investigated as predictors of structural damage by univariate linear (∆ total Sharp/van der Heijde score (TSS) as dependent variable) and logistic (+/-radiographic progression (∆TSS >0) as dependent variable) regression analyses. Variables with p < 0.10 were included in multivariable models. In 70 patients with available HBL1-year data, HBL1-year was median (interquartile range (IQR)) -1.9 (-3.3; -0.26 mg/cm(2)) in the MTX + placebo group and -1.8 (-3.6; 0.06) mg/cm(2) in the MTX + adalimumab group, p = 0.98, Wilcoxon signed-rank. Increased HBL (compared to general population reference values) was found in 26/37 and 23/33 patients in the MTX + placebo and MTX + adalimumab groups, chi-squared = 0.99. In 90 patients with HBL6months data and 2-year radiographic data, HBL6months was independently associated with ∆TSS after 2 years (β = -0.086 (95% confidence interval = -0.15; -0.025) TSS unit/mg/cm(2) increase, p = 0.006) but not with presence of radiographic progression (∆TSS >0) (OR 0.96 (0.92-1.0), p = 0.10). In early RA patients treated with a methotrexate-based treat-to-target strategy, the majority of patients had increased HBL1-year, irrespective of adalimumab; HBL6months was independently associated with ∆TSS after 2 years.

AB - This study aims to investigate 1-year hand bone loss (HBL1-year) in early rheumatoid arthritis (RA) patients treated with a methotrexate (MTX) and intra-articular triamcinolone treat-to-target strategy +/- adalimumab and to determine if HBL6months is associated with radiographic progression after 2 years. In a clinical trial (OPERA) of 180 treatment-naive early RA patients, bone mineral density (BMD) was estimated from hand radiographs with digital X-ray radiogrammetry (DXR) at baseline, after 6 (n = 90) and 12 months (n = 70) of follow-up. Baseline and 2-year radiographs were scored according to the Sharp/van der Heijde method. Baseline characteristics and HBL6months (0-6 months changes in DXR-BMD) were investigated as predictors of structural damage by univariate linear (∆ total Sharp/van der Heijde score (TSS) as dependent variable) and logistic (+/-radiographic progression (∆TSS >0) as dependent variable) regression analyses. Variables with p < 0.10 were included in multivariable models. In 70 patients with available HBL1-year data, HBL1-year was median (interquartile range (IQR)) -1.9 (-3.3; -0.26 mg/cm(2)) in the MTX + placebo group and -1.8 (-3.6; 0.06) mg/cm(2) in the MTX + adalimumab group, p = 0.98, Wilcoxon signed-rank. Increased HBL (compared to general population reference values) was found in 26/37 and 23/33 patients in the MTX + placebo and MTX + adalimumab groups, chi-squared = 0.99. In 90 patients with HBL6months data and 2-year radiographic data, HBL6months was independently associated with ∆TSS after 2 years (β = -0.086 (95% confidence interval = -0.15; -0.025) TSS unit/mg/cm(2) increase, p = 0.006) but not with presence of radiographic progression (∆TSS >0) (OR 0.96 (0.92-1.0), p = 0.10). In early RA patients treated with a methotrexate-based treat-to-target strategy, the majority of patients had increased HBL1-year, irrespective of adalimumab; HBL6months was independently associated with ∆TSS after 2 years.

KW - Journal Article

U2 - 10.1007/s10067-016-3489-1

DO - 10.1007/s10067-016-3489-1

M3 - Journal article

VL - 36

SP - 781

EP - 789

JO - Clinical Rheumatology

JF - Clinical Rheumatology

SN - 0770-3198

IS - 4

ER -

ID: 49936307